Your browser doesn't support javascript.
loading
Pulmonary rehabilitation in Iranian outpatients with mustard gas lung disease: a randomised controlled trial.
Ghanei, Mostafa; Philip, Keir E J; Moghadam, Mohamed R S; Hosseini, Hamed; Babaie, Aliakbar; Roustanezhad, Mohammad; Hopkinson, Nicholas S.
Afiliação
  • Ghanei M; Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran (the Islamic Republic of).
  • Philip KEJ; National Heart and Lung Institute, Imperial College London, London, UK.
  • Moghadam MRS; Centre for Pneumology and Thoracic Surgery, Lung Clinic Hemer, Hemer, Germany.
  • Hosseini H; Clinical Trial Center, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of).
  • Babaie A; Janbazan Medical and Engineering Research Center, Tehran, Iran (the Islamic Republic of).
  • Roustanezhad M; Janbazan Medical and Engineering Research Center, Tehran, Iran (the Islamic Republic of).
  • Hopkinson NS; National Heart and Lung Institute, Imperial College London, London, UK n.hopkinson@ic.ac.uk.
BMJ Open ; 14(5): e083085, 2024 May 28.
Article em En | MEDLINE | ID: mdl-38806414
ABSTRACT

OBJECTIVE:

People with mustard gas lung disease experience cough, sputum, breathlessness and exercise limitation. We hypothesised that pulmonary rehabilitation (PR) would be beneficial in this condition.

DESIGN:

An assessor-blind, two-armed, parallel-design randomised controlled clinical trial.

SETTING:

Secondary care clinics in Iran.

PARTICIPANTS:

60 men with breathlessness due to respiratory disease caused by documented mustard gas exposure, mean (SD) age 52.7 (4.36) years, MRC dyspnoea score 3.5 (0.7), St. George's Respiratory Questionnaire (SGRQ) 72.3 (15.2).

INTERVENTIONS:

Participants were allocated either to a 6-week course of thrice-weekly PR (n=31) or to usual care (n=29), with 6-week data for 28 and 26, respectively. OUTCOME

MEASURES:

Primary endpoint was change in cycle endurance time at 70% baseline exercise capacity at 6 weeks. Secondary endpoints included 6 min walk distance, quadriceps strength and bulk, body composition and health status. For logistical reasons, blood tests that had been originally planned were not performed and 12-month follow-up was available for only a small proportion.

RESULTS:

At 6 weeks, cycle endurance time increased from 377 (140) s to 787 (343) s with PR vs 495 (171) s to 479 (159) s for usual care, effect size +383 (231) s (p<0.001). PR also improved 6 min walk distance+103.2 m (63.6-142.9) (p<0.001), MRC dyspnoea score -0.36 (-0.65 to -0.07) (p=0.016) and quality of life; SGRQ -8.43 (-13.38 to -3.48) p<0.001, as well as quadriceps strength+9.28 Nm (1.89 to 16.66) p=0.015.

CONCLUSION:

These data suggest that PR can improve exercise capacity and quality of life in people with breathlessness due to mustard gas lung disease and support the wider provision of this form of care. TRIAL REGISTRATION NUMBER IRCT2016051127848N1.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Agentes_cancerigenos Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Tolerância ao Exercício / Dispneia / Gás de Mostarda Limite: Adult / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: BMJ Open Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Temas: Agentes_cancerigenos Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Tolerância ao Exercício / Dispneia / Gás de Mostarda Limite: Adult / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: BMJ Open Ano de publicação: 2024 Tipo de documento: Article